VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), ein weltweit führendes Unternehmen für natürliche GMP–konforme cannabinoide Pharmawirkstoffe (API), gibt die [...] Read more »
Brains Bioceutical élargit son offre de cannabinoïdes leaders sur le marché avec le D9-THC et le CBN, et ouvre ainsi de nouvelles possibilités en matière de développement de médicaments
VANCOUVER, Colombie–Britannique, 18 déc. 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), leader mondial dans la fabrication d’ingrédients pharmaceutiques actifs (IPA) à base de [...] Read more »
Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development
VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP–compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the expansion of its [...] Read more »
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- Recursion unveils post–combination technology–enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs
- Platform will focus on first [...] Read more »
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today [...] Read more »
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical–stage global biopharmaceutical company committed to being a [...] Read more »
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- REC–3964 is Recursion’s first new chemical entity developed using the RecursionOS.
- REC–3964 represents a novel, non–antibiotic approach with a unique mechanism of action that binds and blocks [...] Read more »
Fortrea veröffentlicht ersten Bericht zur sozialen Verantwortung des Unternehmens
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) — Read more »
Fortrea Publica Primeiro Relatório de Responsabilidade Social Corporativa
DURHAM, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) — A Read more »
Fortrea publie son premier rapport de Responsabilité Sociale d’Entreprise
DURHAM, Caroline du Nord, 18 oct. 2024 (GLOBE NEWSWIRE) — Read more »
Fortrea Releases Inaugural Corporate Social Responsibility Report
DURHAM, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) — Read more »
Curia verpflichtet sich zum Netto-Null-Standard von SBTi
Albany, New York, Oct. 11, 2024 (GLOBE NEWSWIRE) — Curia, ein führendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute seine Verpflichtung bekannt, die [...] Read more »
Curia s’engage envers la norme de neutralité carbone « net zéro » de la SBTi
Albany, New York, 11 oct. 2024 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, de développement et de fabrication sous contrat de première importance fait part ce [...] Read more »
Curia Se Compromete Ao Padrão SBTi Net-Zero
Albany, NY, Oct. 11, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje seu compromisso de estabelecer [...] Read more »
Curia stellt auf der CPHI WW in Mailand eine neue Marke vor
ALBANY, New York, Oct. 08, 2024 (GLOBE NEWSWIRE) — Curia, ein führendes Unternehmen für Auftragsforschung, –entwicklung und –herstellung, hat heute seine neue Marke vorgestellt. Das Update führt eine [...] Read more »